bluechew zepbound tirzepatide partnership A pharmacy benefit manager stopped covering a GLP-1 for obesity. Now there's a lawsuit Generic Zepbound Explained: The Patent

This risk appears to increase with treatment duration beyond 1.5 years

Phase 3 TRIUMPH trial results The Phase 3 TRIUMPH-4 trial, announced in late 2025, confirmed and even improved on the Phase 2 numbers

If your next dose is less than two days away, its generally best to skip the missed dose and resume your regular schedule

Non-invasive assessment of fibrosis risk using the FIB-4 score is recommended in UK practice (NICE NG49)

Convenient cartridge format: The cartridge allows controlled dosing when used with a compatible delivery device

Xinfuda provides OEM/ODM support including device appearance, color, branding, packaging and project documentation